Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX GmbH has received a grant from Hamburgische Investitions und Förderbank.

December 30, 2015


2cureX’s German subsidiary 2cureX GmbH has received funding (EUR 450.000) from Hamburgische Investitions und Förderbank (IFB Hamburg) to broaden the IndiTreat™ product portfolio. 2cureX’s Individual Treatment test, IndiTreat™ has been developed and is presently clinically evaluated in colorectal cancer patients. The funding from IFB will allow 2cureX in collaboration with University Medical Center Hamburg-Eppendorf (UKE) to address other types solid cancers.